JCR Pharmaceuticals (JCRRF) Stock Price, News & Analysis

Company Overview

JCR Pharmaceuticals Co., Ltd. is a Japan-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases, regenerative medicine applications and other conditions with significant unmet medical needs. The company conducts research, development, manufacturing and marketing of prescription medicines, with an emphasis on biologic therapies and innovative drug-delivery technologies.

JCR’s products include therapies for lysosomal storage disorders and regenerative medicine. Its flagship technology, J-Brain Cargo, is designed to help transport therapeutic proteins across the blood-brain barrier. The company’s pabinafusp alfa product, marketed in Japan as IZCARGO, uses this platform to treat Hunter syndrome, also known as mucopolysaccharidosis type II. JCR has also developed TEMCELL HS Inj., a mesenchymal stem-cell therapy used in Japan for steroid-refractory acute graft-versus-host disease.

Founded in 1975, JCR Pharmaceuticals is headquartered in Ashiya, Hyogo Prefecture, Japan. Its commercial operations are concentrated in Japan, while the company seeks to expand access to its technologies and products through international collaborations, licensing arrangements and partnerships. JCR continues to develop therapies for rare and genetic diseases, including programs intended to address disorders affecting the central nervous system.

Key Stats

• Today's Range: $3.73 to $3.73
• 50-Day Range: $3.31 to $3.73
• 52-Week Range: $3.15 to $3.73
• Volume: N/A
• Average Volume: 260 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/11/2026
• Next Earnings (Estimated): 10/29/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:JCRRF
• CIK: N/A
• Web: www.jcrpharm.co.jp
• Phone: 81 7 9732 8591
• Fax: N/A
• Employees: 934
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A